ALFA Finder| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 614.0 | 564.1 | 487.4 |
| Other income | 6.4 | 12.6 | 13.4 |
| Total income | 620.4 | 576.7 | 500.8 |
| Profit before exceptional items & tax | 75.1 | 75.3 | 53.6 |
| Exceptional items | 0.0 | 1.3 | 0.0 |
| Profit before tax | 75.1 | 76.6 | 53.6 |
| Net profit | 55.0 | 50.0 | 38.1 |
| Operating margin | 12.1% | 13.3% | 10.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +44.40% |
|---|---|
| Net profit, quarter on quarter | +10.00% |
| Revenue, year on year | +26.00% |
| Operating profit, year on year | +70.90% |
| Operating profit, quarter on quarter | +9.60% |
BSE results filing, NSE: AGARWALEYE. Figures extracted from the filing.
Dr. Agarwals Health Care Ltd: key numbers
- Share price
- ₹553.60
- Market cap
- ₹17,555 Cr
- Revenue (annual)
- ₹2,080 Cr
- Net profit (annual)
- ₹133.2 Cr
- P/E (TTM)
- 101.2×Sector 54.5×
- Promoter holding
- 32.33%-0.01% QoQ
- FII holding
- 49.56%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dr. Agarwals Health Care Ltd
All →Dr. Agarwals Health Care Other Announcement
Dr. Agarwal's Health Care submitted ICRA's monitoring agency report for the quarter ended September 30, 2026. ICRA reports no material deviation in IPO proceeds utilisation.
Dr. Agarwals Health Care Employee Stock Options
Dr. Agarwal's Health Care allotted 54,728 equity shares to employees on exercise of ESOP 2022 options. Paid-up capital rose to 31,70,99,111 shares, with no cash consideration stated.
Dr. Agarwals Health Care Earnings Call Transcript: Key Takeaways
Q2 FY27 revenue ₹655 Cr (+31.4% YoY) and PAT ₹57 Cr (+55.8%), network-led growth; India EBITDA margin flat near 28%.
Dr. Agarwals Health Care Management Change
Dr Agarwals Health Care reports Mr. Amar Agarwal's redesignation from Chairman and Non-Executive Director to Executive Director, effective 1 November 2026. The change was approved at a board meeting held on 5 November 2026.
Dr. Agarwals Health Care Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹655 Cr (+31.4% YoY) and PAT ₹57 Cr (+55.8%). H1 FY27 revenue ₹1,269 Cr (+28.7%), PAT ₹112 Cr (+50.1%). Strategy is aggressive facility expansion, with 65 FY27E additions.
Dr. Agarwals Health Care Financial Results
Dr. Agarwal's H1 FY27 revenue rose 28.7% to Rs 1,269 crore; PAT rose 50.1% to Rs 112 crore. Amar Agarwal's executive chairman appointment awaits postal ballot approval.